Teriparatide
A bone-building drug. A parathyroid-hormone fragment (PTH 1-34), FDA-approved as Forteo for severe osteoporosis; Abaloparatide (Tymlos) is its newer sibling analog. Anabolic for bone, the opposite of bisphosphonates.
Teriparatide: A bone-building drug. A parathyroid-hormone fragment (PTH 1-34), FDA-approved as Forteo for severe osteoporosis; Abaloparatide (Tymlos) is its newer sibling analog. Anabolic for bone, the opposite of bisphosphonates. Teriparatide is the active piece of parathyroid hormone (PTH 1-34).
Teriparatide is the active piece of parathyroid hormone (PTH 1-34). FDA-approved as Forteo for severe osteoporosis. Unlike most osteoporosis drugs, it actually builds new bone instead of just slowing bone loss. Daily injection, capped at 24 months total lifetime use per FDA label.
FDA-approved drug used for severe osteoporosis. Federations don't typically address it.
Approved as Forteo (2002) for severe osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and glucocorticoid-induced osteoporosis.
FDA-approved drug products containing this substance are available. Compounded versions are not FDA-approved.
Yes, endocrinology and rheumatology providers prescribe it for osteoporosis. ~24 months is the standard course; the FDA removed the hard 2-year lifetime cap in Nov 2020, so longer use is label-permitted if high fracture risk persists.
Who it's for
- →Severe osteoporosis under endocrine care
- →Stress-fracture recovery (off-label)
- →Older adults with high fracture risk
What to expect
- Week 1
Subtle. Some calcium-flux symptoms early.
- Week 4
Bone markers improving on labs.
- Week 8
Cumulative bone density gains over months, not weeks.
Looking at Teriparatide? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for Teriparatide.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Recombinant first 34 amino acids of parathyroid hormone (PTH 1-34). Intermittent daily dosing favors osteoblast activity over osteoclast activity, building new bone, opposite of bisphosphonates which slow bone breakdown.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Paget's disease
- ⚠Prior radiation to bone
- ⚠Hypercalcemia
- ⚠Active malignancy
- ⚠Pregnancy / nursing
Bloodwork to monitor
- • Serum calcium baseline + at 1 month + every 6 months
- • 25-OH vitamin D
Common mistakes
- • Continuing past ~2 years without an ongoing high-fracture-risk reason (the hard lifetime cap was removed in 2020)
- • Skipping calcium / vitamin D adequacy first
- • Underestimating the prescription-and-monitoring requirement
What it actually is
Teriparatide, sold as Forteo, is the first 34 amino acids of parathyroid hormone. It is an approved treatment for severe osteoporosis and it is unusual among bone drugs: nearly everything else slows bone breakdown, while teriparatide actively builds new bone. It is one of the best-evidenced compounds in this catalog, with 286 indexed randomised-trial records.
The trick is timing. Parathyroid hormone continuously elevated — as in an overactive parathyroid gland — strips calcium from bone. The same hormone delivered as a brief daily spike does the opposite: it activates bone-building osteoblasts more than bone-resorbing osteoclasts, and net bone mass increases. A once-daily injection with a one-hour half-life produces exactly that spike-and-clear pattern. Give the same drug continuously and you would get bone loss instead, which is a genuinely counterintuitive piece of pharmacology.
Forms, and which is which
Once-daily 20 mcg subcutaneous injection, refrigerated, on prescription for severe osteoporosis.
Verdict: The reference form.
Available as patents lapsed. Same molecule, pharmacy-grade.
Verdict: The best value legitimate route.
A related PTH-family analog with its own approval and trial programme.
Verdict: Same class, different molecule, choose with a clinician.
Makes no sense when biosimilars exist. It also requires cold-chain handling that unregulated supply does not provide.
Verdict: Quality risk for no reason.
What it is claimed to do, graded
The approved indication, with 23 phase 3 and 286 indexed randomised-trial records plus 167 meta-analyses. Among the most solidly evidenced claims on the whole site.
The defining property, and what separates it from bisphosphonates. Demonstrated on bone-formation markers and imaging.
The DATA-Switch trial showed that going from denosumab to teriparatide produced transient bone loss while the reverse order did not — a genuinely practice-changing result and a reason this is a specialist decision.
Studied off-label with encouraging but not definitive results.
The rodent signal has not appeared in post-marketing human surveillance, and FDA removed the boxed warning in 2020. It remains a labelled warning rather than a demonstrated human risk, and the conditions that raise baseline osteosarcoma risk are still reasons to avoid it.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • Genuinely anabolic for bone, which almost nothing else is
- • An enormous randomised evidence base and long clinical experience
- • The boxed warning was removed in 2020, the rodent signal not having appeared in human surveillance
- • Biosimilars have made it substantially cheaper
- • Daily injection, refrigerated. The absolute lifetime cap is gone, but the label still says use beyond two years should be considered only if fracture risk remains or returns to high
- • Expensive even with biosimilars, and usually reserved for severe osteoporosis
- • Order of therapy matters: coming off it without a follow-on antiresorptive loses the gains
- • Raises calcium, so it is wrong for anyone already hypercalcaemic
- • Should be avoided with prior skeletal radiation or Paget's disease because of baseline osteosarcoma risk — the label's formal contraindication is severe hypersensitivity
When to stop
- • Symptoms of high calcium: nausea, constipation, confusion, excessive thirst
- • Persistent bone pain in a specific spot
- • A new bone cancer diagnosis, or bone metastases
- • Reaching the planned course length without a follow-on plan — that gap is where the gains are lost
Interactions
Teriparatide transiently raises calcium, and high calcium predisposes to digoxin toxicity.
Order matters and is not symmetrical. Switching from denosumab to teriparatide produced transient bone loss in DATA-Switch; the other direction did not.
Usually sequenced rather than combined, and stopping teriparatide without a follow-on antiresorptive loses the gains.
Normally taken alongside, since the drug needs substrate to build bone.
Both raise calcium.
Is this for you?
- • People with severe osteoporosis or a high fracture risk, under specialist care
- • Anyone who has failed or cannot tolerate antiresorptive therapy
- • You have had a severe hypersensitivity reaction to teriparatide — that is the label's formal contraindication
- • You have Paget's disease of bone, unexplained raised alkaline phosphatase, or prior skeletal radiation — all raise baseline osteosarcoma risk and the label says avoid
- • You have bone metastases or a history of skeletal malignancy
- • You are already hypercalcaemic, or pregnant or nursing
The one number
Sources for the claims above
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (DATA-Switch)
- Efficacy and safety versus bisphosphonates and denosumab
- Drug review
Drug & supplement interactions
- ⚠Digitalis (digoxin): teriparatide-induced calcium fluctuations may sensitize to digitalis effects
- ⚠Thiazide diuretics: may cause hypercalcemia
- ⚠Standard ~2-year course (the hard 24-month lifetime cap was removed in 2020), combine with calcium and vitamin D adequacy
New to Teriparatide? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about Teriparatide or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is Teriparatide?+
Is Teriparatide FDA approved?+
Is Teriparatide legal?+
Is Teriparatide banned by WADA?+
Are you still natty after taking Teriparatide?+
Do doctors prescribe Teriparatide?+
What's the typical dose of Teriparatide?+
What are the side effects of Teriparatide?+
How long until Teriparatide starts working?+
What can you stack with Teriparatide?+
Where do people get Teriparatide?+
Common questions about Teriparatide
Tracked alongside Teriparatide
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Healing
Synthetic peptide derived from a stomach protein. Used to speed up tendon, ligament, and gut healing.
A fragment of Thymosin Beta-4. Drives cell migration and tissue repair, used for chronic soft-tissue stuff.
A compound studied for calming nerve pain and inflammation without raising red blood cells. An EPO-derived peptide that targets the innate-repair receptor without the red-blood-cell side of erythropoietin, studied for neuropathic pain, sarcoidosis, and diabetic complications.
A gut drug that helps people with short bowel syndrome absorb more nutrients. A recombinant GLP-2 analog, FDA-approved in 2012 for short bowel syndrome with intestinal failure; it hits a different receptor and indication than the GLP-1 weight-loss drugs.